An interventional study of Oral versus intravenous administration of antibacterial treatment in Acute Appendicitis, Acute Appendicitis With Rupture and Acute Appendicitis Without Peritonitis, sponsored by North Estonia Medical Centre. Status unknown at 1 site in Estonia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-01.
Sponsored by North Estonia Medical Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Short Post-operative Antibacterial Therapy in Complicated Appendicitis: Oral Versus Intravenous is a prospective randomized controlled trial comparing 24 hour intravenous antibacterial therapy to 24 hour oral antibacterial therapy after surgery in complicated appendicitis.
421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.
This study's planned enrollment of 100 is below the median of 116 across 254 interventional studies indexed under Appendicitis.
Browse Appendicitis studies →North Estonia Medical Centre is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients diagnosed with acute appendicitis and are candidates for laparoscopic appendectomy.
Exclusion Criteria:
Patients with compromised immune system (, diabetes), ongoing or completed radio-chemotherapy in past 5 years, prosthetic heart valve, vascular prosthesis, pregnancy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
S.Augmentin 1,2g x 3 i/v
Other: Oral versus intravenous administration of antibacterial treatment
T.Augmentin 1g x 3 p/o
Other: Oral versus intravenous administration of antibacterial treatment
Mode of administration of antibacterial treatment
Infectious complications
Time frame: 30 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2020 (actual). Primary completion is estimated for Dec 2021, 13 months after the start.
Of 92 non-industry interventional studies with no phase under Appendicitis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 13 months is below that.
Counting every sponsor, half of 94 studies reached it within 19 months; a quarter within 10 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
North Estonia Medical Centre